The PD-1 (programmed death-1)/PD-L1 (PD-ligand 1) checkpoint is a critical regulator of activated T cellcancer cell interactions, defending tumor cells against immune destruction. Nano-diamino-tetrac (NDAT; Nanotetrac) is an anticancer/anti-angiogenic agent targeted to the thyroid hormone-tetrac receptor on the extracellular domain of integrin avb3. NDAT inhibits the cancer cell PI3-K and MAPK signal transduction pathways that are critical to PD-L1 gene expression. We examined actions in vitro of thyroid hormone (L-thyroxine, T 4 ) and NDAT on PD-L1 mRNA abundance (qPCR) and PD-L1 protein content in human breast cancer (MDA-MB-231) cells and colon carcinoma (HCT116 and HT-29) cells. In MDA-MB-231 cells, a physiological concentration of T 4 (10 À7 M total; 10 À10 M free hormone) stimulated PD-L1 gene expression by 38% and increased PD-L1 protein by 2.7-fold (p < 0.05, all changes). NDAT (10 À7 M) reduced PD-L1 in T 4 -exposed cells by 21% (mRNA) and 39% (protein) (p < 0.05, all changes).
Introduction
The PD-1 (programmed death-1)/PD-L1 (PD-ligand 1) checkpoint is an essential regulator of activated T cell-tumor cell interactions [1] [2] [3] . The checkpoint defends tumor cells against immune destruction. Generated by tumor cells, PD-L1 (or B7-H1) protein engages PD-1 to suppress activated T cell engagement with tumor cells; the liganding may also serve to induce apoptosis of T cells. Overexpression of PD-L1 is observed in melanoma, pancreatic and lung cancer cells, among others, and may correlate with decreased patient survival [1] . Antibodies directed at PD-L1 have shown promise as immunotherapy for melanoma, lung and kidney cancers and hematological malignancies [2, 4] , although clinical activity of the antibodies appears to be limited to a minority of each of these conditions [5] [6] [7] . Two antibodies to PD-L1 have received limited anticancer FDA approval and additional PD-L1 antibodies are in clinical trials [3, 4] .
Activation of the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3-K) signal transducing pathways is critical to expression of the PD-L1 gene in cancer cells [8, 9] . The epidermal growth factor receptor (EGFR) may drive PD-L1 expression [10] and interferon-c (IFN-c) is a potent endogenous inducer of expression of PD-L1 [11] . Nano-diamino-tetrac (NDAT; Nanotetrac) (Fig. 1) is an anticancer/anti-angiogenic agent directed at a receptor for thyroid hormone and tetraiodothyroacetic acid (tetrac) on the extracellular domain of integrin avb3 [12, 13] . Expression of the integrin is largely by cancer cells and dividing endothelial cells, so that normal nondividing cells are very limited targets of NDAT [12] . NDAT is made by the covalent bonding via a linker of tetrac, a deaminated derivative of L-thyroxine (T 4 ), to poly (lactic-co-glycolic acid) (PLGA); this prevents cellular uptake of tetrac and restricts actions of the tetrac-linker molecule to the hormone receptor on the extracellular domain of avb3 [14] . NDAT inhibits the PI3-K and MAPK pathways in cancer cells [12, 15] and blocks expression of a panel of genes critical to cancer cell survival pathways, and the EGFR gene [13] . Tetrac is also known to block enhancement by thyroid hormone of actions of IFN-c [16, 17] . Against this background, we studied the immune system-independent actions of NDAT and T 4 on PD-L1 expression that are initiated at integrin avb3 in human cancer cells. T 4 was studied because it is the principal thyroid hormone ligand at the cell surface hormone receptor on integrin avb3 [12, 18] .
Experimental methods

Cells
Human breast cancer MDA-MB-231 (ER-negative, ATCC 
Statistical analysis
Immunoblot and nucleotide densities were compared by IBM SPSS Statistics software, version 19.0 (SPSS Inc., Chicago, IL USA). Two-tailed Student's t-test determined significance, with p values <0.05 (*, # or §), <0.01 (**, ## or § §) and <0.001 (***, ### or § § §).
Results
Thyroid hormone induces PD-L1 expression that is inhibited by Nano-diamino-tetrac (NDAT) in human breast cancer MDA-MB-231 cells
Triple-negative human breast carcinoma MDA-MB-231 cells were treated with different concentrations of T 4 (10 À8 to 10 À6 M)
for 24 h and cells were harvested and total RNA was extracted. The concentration of 10 À7 M T 4 yields a physiological free hormone concentration [19] . qPCR of PD-L1 revealed that PD-L1 mRNA was significantly induced by thyroid hormone on a concentrationdependent basis and the increase was 38% at 10 À7 M ( Fig. 2A) . (11%), but statistically significant, reduction in PD-L1 mRNA abundance in the absence of added T 4 (basal PD-L1 expression).
Parallel studies were conducted to study the effect of thyroid hormone on PD-L1 protein accumulation. MDA-MB-231 cells were treated with different concentrations of T 4 for 24 h. Total proteins were extracted and western blot analysis of PD-L1 was conducted. Results in Fig. 2C show that T 4 at 10 À7 M induced a 2.7-fold increase in PD-L1 protein abundance. The T 4 -induced PD-L1 protein was subject to complete inhibition by NDAT. In addition, NDAT reduced basal content of PD-L1 protein by 32% in these breast cancer cells (Fig. 2D ).
Thyroid hormone induces PD-L1 expression that is inhibited by NDAT in human colorectal cancer HCT116 cells
Human colorectal cancer HCT116 cells were treated with different concentrations of thyroid hormone (10 À8 to 10 À6 M) for 24 h, cells were harvested and total RNA was extracted. PD-L1 mRNA was significantly induced by thyroid hormone (T 4 ) in a concentration-dependent manner (10 À8 to 10 À7 M) ( 24 h with 10 À7 M T 4 in the presence of NDAT (10 À7 M), thyroid hormone-induced PD-L1 mRNA accumulation was significantly reduced (33%, p < 0.01) (Fig. 3B) . Basal mRNA abundance was decreased by 35% (p < 0.001) in the presence of NDAT. Parallel studies of PD-L1 protein accumulation in HCT116 cells showed that PD-L1 protein was increased by T 4 on a concentration-dependent basis at 10 À8 to 10 À7 M (Fig. 3C) . However,
reduced basal (no added T 4 ) PD-L1 expression by 31% (p < 0.05) and decreased T 4 -stimulated PD-L1 by 66% (p < 0.01) (Fig. 3D) .
The above studies were also conducted in a second human colorectal cancer cell line, HT-29. In these cells, PD-L1 mRNA abundance increased 62% in response to T 4 (10 À7 M, p < 0.05) (Fig. 4A) . In contrast to results obtained in HCT116 cells, the supraphysiological concentration of 10 À6 M T 4 was even more effective in inducing expression of PD-L1 mRNA than was 10 À7 M T 4 . NDAT significantly decreased basal (30%) and T 4 -stimulated levels of PD-L1 mRNA (45%) (Fig. 4B) . The basal PD-L1 protein level in HT-29 colon carcinoma cells was enhanced by T 4 in a concentrationdependent manner (Fig. 4C) . NDAT (10 À7 M) reduced basal PD-L1 expression by 44% (p < 0.05) and decreased T 4 -stimulated PD-L1 by 54% (p < 0.01) (Fig. 4D ).
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Activation of ERK1/2 is involved in thyroid hormone-induced PD-L1 expression
Activation of ERK1/2 has been shown to be essential for thyroid hormone-induced biological activities activated ERK1/2 is involved in thyroid hormone-induced PD-L1 expression.
Discussion
We have previously shown that T 4 at physiological concentrations of free hormone is anti-apoptotic [20] and pro-angiogenic [21] . These properties are desirable in normal cells-e.g., myocardiocytes, neurons-and in normal tissues, but serve undesirably to support tumors. In the studies reported here, T 4 upregulated transcription of PD-L1 in cancer cells, serving to defend such cells against immune system destruction. In contrast, such an action by the hormone on nonmalignant cells would desirably defend against destructive autoimmune processes.
A substantial number of actions of thyroid hormone on cancer cells that support survival of such cells have been shown to be nongenomic in origin and initiated at a thyroid hormone receptor described on the extracellular domain of integrin avb3 [12, 19] .
Like other integrins, avb3 is a structural protein of the plasma membrane that is important to extracellular matrix protein-cell interactions. The observation in the current studies that NDAT inhibited the action of T 4 on PD-L1 expression in the tumor cells studied means that the hormone receptor on avb3 mediated the event; that is, the inhibitory effects of NDAT on tumor cells and dividing endothelial cells are limited to the thyroid hormone receptor on the extracellular domain of integrin [12] . In contrast to T 4 , and in part due to its action to inhibit binding of T 4 at its receptor on the integrin, NDAT has pro-apoptotic and anti-angiogenic activities. The current in vitro studies indicate that NDAT non-immunologically also blocks thyroid hormone actions on the PD-L1 component of the PD-1/PD-L1 checkpoint.
In the clinical setting, the thyroid hormone axis is usually normal and thus the present studies suggest that activity of the PD-1/ PD-L1 tumor cell self-defense system is in part due to endogenous T 4 . That endogenous thyroid hormone may support cancers of various types has been suggested in clinical studies of breast cancer [22], renal cell carcinoma [23] , head and neck cancers [24] and glioblastoma [25] . A recent observational study indicates that maintenance of the euthyroid state with 3,5,3 0 -triiodo-L-thyronine (T 3 )-with pharmacologic elimination of T 4 (=euthyroid hypothyroxinemia)-prolongs survival in patients with end stage cancers [26] . In vitro studies also have shown a trophic effect of the hormone on cancer cell proliferation [15, [27] [28] [29] . The results presented here raise the possibility that PD-L1-directed immunotherapy is opposed by endogenous T 4 and that such therapy might be improved clinically by lowering of circulating T 4 by pharmacologic intervention.
Interestingly, in both of the colon cancer cell lines studied here, NDAT also reduced PD-L1 protein content in the absence of T 4 . Basal levels of PD-L1 protein in MDA-MB-231 breast cancer cells decreased only minimally in response to NDAT. Thus, there is variation in susceptibility of the gene to regulation via the thyroid hormone-NDAT receptor on avb3. In addition, the magnitude of the response to T 4 of PD-L1 mRNA and protein levels varied among the cell lines studied. This is not surprising, given the inconsistent importance of PD-L1 to tumor cell defense illustrated by the variable clinical efficacy to-date of immunotherapy targeted at the PD-1/PD-L1 checkpoint [5] .
Immunotherapy directed at the PD-1/PD-L1 checkpoint bears a clinical risk of induction of autoimmune destructive activity in nonmalignant tissues [30] . Thus, alternatives to antibodies are desirable that pharmacologically target the PD-1/PD-L1 axis specifically in cancer cells. The studies reported here indicate that NDAT may be one such non-immunologic alternative. The receptor target of NDAT is primarily expressed by cancer cells, thus limiting exposure of nonmalignant cells to disruption of the PD-1/PD-L1 checkpoint by the agent. The drug also has pro-apoptotic and antiangiogenic activities that involve multiple mechanisms regulated from integrin avb3 [11, 12] . 
Summary
NDAT significantly and non-immunologically suppresses T 4 -induced PD-L1 gene expression in human colon and breast cancer cells and significantly reduces cell content of PD-L1 protein.
Nonmalignant cells and normal immune system surveillance will escape this novel effect of NDAT because normal cells, except for rapidly dividing endothelial cells and osteoclasts, express little avb3. In the clinical setting, the PD-L1 gene is invariably exposed to host thyroid hormone and we speculate that host circulating T 4 supports defensive PD-1/PD-L1 checkpoint activity in tumor cells. These results indicate that the PD-1/PD-L1 checkpoint is subject to non-immunologic, pharmacological regulation by NDAT.
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